Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Rating of “Hold” from Analysts

Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $2.00.

Several equities analysts have issued reports on HRTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd.

Institutional Trading of Heron Therapeutics

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Heron Therapeutics during the second quarter worth $4,503,000. Orbimed Advisors LLC purchased a new position in Heron Therapeutics in the first quarter worth $7,855,000. Millennium Management LLC raised its position in Heron Therapeutics by 2,785.2% in the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after acquiring an additional 6,921,405 shares in the last quarter. Tejara Capital Ltd acquired a new stake in Heron Therapeutics in the second quarter valued at $2,779,000. Finally, Tang Capital Management LLC lifted its holdings in Heron Therapeutics by 81.2% in the fourth quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock valued at $8,125,000 after acquiring an additional 2,800,000 shares during the period. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Stock Up 5.3%

Heron Therapeutics stock opened at $0.34 on Thursday. The stock has a 50 day moving average of $0.44 and a two-hundred day moving average of $0.81. Heron Therapeutics has a twelve month low of $0.30 and a twelve month high of $1.57. The stock has a market capitalization of $64.53 million, a price-to-earnings ratio of -1.79 and a beta of 1.65. The company has a current ratio of 2.53, a quick ratio of 1.51 and a debt-to-equity ratio of 17.51.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter. Heron Therapeutics had a negative return on equity of 265.11% and a negative net margin of 22.52%.The company had revenue of $37.67 million for the quarter, compared to analysts’ expectations of $42.19 million. As a group, research analysts expect that Heron Therapeutics will post -0.09 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.